Recent development of engineered T cell therapies has demonstrated remarkable efficacy and brought hope to cancer patients. However, many challenges still remain in their cell productions since patients’ T cells as starting materials are exhausted and weak, have a vast variation in quality, and are very hard to expand. For those reasons, iPSC-derived engineered immune cells gain increasing attentions from many biotech companies and pharmaceutical companies. Thyas is a start-up company, pioneering producing iPS cell-derived T cells (iPS-T), NK cells, and other immune cells for the treatment of cancers. Thyas’ technology, developed by Dr. Shin Kaneko, a professor at the Center of iPS cell Research and Application (CiRA), Kyoto University, Japan, makes it possible to manufacture the large number of iPSC-derived immune cells with potent cytotoxicity, significant proliferative capacity, and excellent persistency in vivo. The therapeutic benefits are expected to be treating patients with no/few or exhausted immune cells, breaking through an immunosuppressive microenvironment with large numbers of iPSC-derived immune cells, and completely removing cancer cells without significant side effects. Thyas’ first product is an off-the-shelf type of iPS-T cells targeting solid tumors with a tumor antigen specific T cell receptor (TCR-iPS-T), which is currently in a preclinical stage. In addition, Thyas is in collaboration with Kyoto University to support an ongoing clinical trial with iPSC-derived NK cells (iPS-NK) in Japan. Importantly, those iPSC-derived immune cells could be a platform to take any CARs or TCRs. Demonstration of safety and preliminary efficacy of those products in clinical trials would promote the use of iPS cell-derived immune cells for many other cancers through alliances with biotech companies and pharmaceutical companies.